快速等离子检测市场规模、份额、样本成长分析、检测检体、应用、最终用户、地区 - 产业预测，2025 年至 2032 年

2023 年全球快速血浆反应检测市场规模为 28 亿美元，预计将从 2024 年的 30.9 亿美元成长到 2032 年的 67.7 亿美元，预测期内（2025-2032 年）的复合年增长率为 10.3%。

男男性行为者和孕妇等高危险群中梅毒发病率的上升显着增加了对快速血浆反应检测的需求。这些检测系统的技术进步尤其有利于处理大量检测的实验室，因为它们可以简化样本处理流程并提高通量。此外，政府性行为感染感染 (STI)筛检的措施预计将进一步刺激市场成长。人们对快速照护现场检测 (POC) 的偏好日益增长，也可能推动该检测的普及，尤其是在新兴市场，因为这些市场对梅毒和其他性传播感染的认识正在不断提高。然而，资源匮乏地区的获取途径有限、来自替代诊断方法的竞争以及监管障碍等挑战可能会阻碍 2032 年以后的市场渗透。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析

快速等离子体反应测试市场规模（检体），复合年增长率（2025-2032）

• 市场概览
• 血
• 血清
• 电浆

快速等离子体反应测试市场规模（按测试类型划分）及复合年增长率（2025-2032）

• 市场概览
• 常规测试
• 快速检测

快速等离子反应测试市场规模（依应用）及复合年增长率（2025-2032）

• 市场概览
• 诊断
• 筛检

快速等离子体反应测试市场规模（以最终用户划分）及复合年增长率（2025-2032）

• 市场概览
• 医院和诊所
• 诊断实验室
• 研究所

快速等离子体反应测试市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益同比对比（2022-2024 年）

主要企业简介

• Thermo Fisher Scientific Inc.（USA）
• Danaher Corporation（USA）
• Abbott Laboratories（USA）
• F. Hoffmann-La Roche AG（Switzerland）
• Siemens Healthineers AG（Germany）
• Bio-Rad Laboratories, Inc.（USA）
• Merck KGaA（Germany）
• Quest Diagnostics（USA）
• Cardinal Health, Inc.（USA）
• bioMerieux SA（France）
• Becton, Dickinson and Company（BD）（USA）
• Sekisui Diagnostics（USA）
• Meridian Bioscience, Inc.（USA）
• Arlington Scientific Inc.（USA）
• Immunostics Inc.（USA）
• Novacyt Group（France）
• Trinity Biotech plc（Ireland）
• Atlas Medical GmbH（Germany/UK）
• Sclavo Diagnostics International Srl（Italy）

结论和建议

Global Rapid Plasma Reagin Test Market size was valued at USD 2.8 billion in 2023 and is poised to grow from USD 3.09 billion in 2024 to USD 6.77 billion by 2032, growing at a CAGR of 10.3% during the forecast period (2025-2032).

The rising incidence of syphilis, particularly among high-risk populations such as men who have sex with men and pregnant women, is significantly increasing the demand for rapid plasma reagin tests. Technological advancements in these testing systems facilitate streamlined sample processing and enhance throughput, making them particularly beneficial for high-volume laboratories. Additionally, government initiatives focused on sexually transmitted infection (STI) screening are expected to further stimulate market growth. The growing preference for point-of-care (POC) testing due to quick results will also drive adoption, especially in emerging markets where awareness of syphilis and other STIs is on the rise. However, challenges like limited access in low-resource settings, competition from alternative diagnostics, and regulatory hurdles may hinder market penetration through 2032 and beyond.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Rapid Plasma Reagin Test market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Rapid Plasma Reagin Test Market Segments Analysis

Global Rapid Plasma Reagin Test Market is segmented by Specimen, Test Type, Application, End User and region. Based on Specimen, the market is segmented into Blood, Serum and Plasma. Based on Test Type, the market is segmented into Traditional Tests and Rapid Tests. Based on Application, the market is segmented into Diagnostics and Screening. Based on End User, the market is segmented into Hospitals & Clinics, Diagnostic Laboratories and Research Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Rapid Plasma Reagin Test Market

The Global Rapid Plasma Reagin (RPR) Test market is experiencing significant growth driven by the rising prevalence of chronic diseases and a heightened awareness of health and wellness. This surge in demand for preventive healthcare is rooted in the critical need for early syphilis detection through routine screenings, which prevents complications and limits the infection's spread. Healthcare providers are increasingly incorporating RPR testing into standard preventive care practices, particularly for high-risk populations. This proactive strategy supports overarching public health initiatives aimed at lowering sexually transmitted infection (STI) rates and encourages regular screenings to promote better health outcomes.

Restraints in the Global Rapid Plasma Reagin Test Market

The Global Rapid Plasma Reagin Test market faces obstacles due to various biological factors, including autoimmune disorders and other infections, which can trigger non-specific reactions and yield inaccurate results. This often necessitates additional confirmatory testing, potentially delaying both diagnosis and treatment. Such limitations can undermine the perceived reliability of the rapid plasma reagin test among healthcare professionals, prompting them to favor alternative diagnostic approaches. As a result, this reluctance may hinder the broader acceptance and utilization of rapid plasma reagin tests, ultimately affecting their long-term presence in the market.

Market Trends of the Global Rapid Plasma Reagin Test Market

The Global Rapid Plasma Reagin (RPR) Test market is witnessing a significant trend towards the integration of RPR testing within multiplex diagnostic platforms, streamlining STI screening processes. This innovative approach facilitates the simultaneous detection of various infections such as HIV, syphilis, and hepatitis from a single sample, thereby reducing both testing time and associated costs. Particularly beneficial in resource-limited settings, this trend enhances logistical efficiency and promotes broader RPR adoption. By embedding RPR into comprehensive diagnostic strategies, the market is not only improving STI management but also significantly expanding overall diagnostic coverage, ultimately contributing to better public health outcomes globally.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Rapid Plasma Reagin Test Market Size by Specimen & CAGR (2025-2032)

• Market Overview
• Blood
• Serum
• Plasma

Global Rapid Plasma Reagin Test Market Size by Test Type & CAGR (2025-2032)

• Market Overview
• Traditional Tests
• Rapid Tests

Global Rapid Plasma Reagin Test Market Size by Application & CAGR (2025-2032)

• Market Overview
• Diagnostics
• Screening

Global Rapid Plasma Reagin Test Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals & Clinics
• Diagnostic Laboratories
• Research Institutes

Global Rapid Plasma Reagin Test Market Size & CAGR (2025-2032)

• North America (Specimen, Test Type, Application, End User)
  • US
  • Canada
• Europe (Specimen, Test Type, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Specimen, Test Type, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Specimen, Test Type, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Specimen, Test Type, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Thermo Fisher Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cardinal Health, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bioMerieux SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sekisui Diagnostics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Meridian Bioscience, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arlington Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immunostics Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novacyt Group (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Trinity Biotech plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Atlas Medical GmbH (Germany/UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sclavo Diagnostics International S.r.l. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations